



## press release

### **Serentis Appoints Peter Keen as New Corporate Development and Finance Director**

Cambridge, UK [30th October, 2007] - Serentis, a UK-based biopharmaceutical company innovating, acquiring and developing dermatological and wound care products, announces today that it has appointed Peter Keen as Corporate Development and Finance Director.

Peter joins from the venture capital company DFJ Esprit and brings a wealth of experience in fund raising, operational management and deal making in life-science companies.

He has held senior executive positions in biopharmaceutical and venture capital companies. In 1996 Peter co-founded the life sciences VC firm Merlin Biosciences, where he was UK Managing Director until early 2003. More recently he was Chief Financial Officer of Arakis Ltd where he led the successful £106m trade sale, having been responsible for Merlin's original seed investment in 2000. Before Merlin, Peter gained 12 years operational experience in the healthcare and biotechnology industries with Agricultural Genetics, Cambridge Life Sciences and Chiroscience where he was a co-founder and where he was responsible for the IPO in 1994.

Peter is also a non-executive director of Ark Therapeutics Group plc, Abcam plc and the Biotech Growth Trust plc.

Tim Sharpington, Chief Executive Officer of Serentis said "We are delighted to welcome Peter to Serentis. It is an exciting time for the company and Peter's financial expertise and experience of growing businesses both organically and through acquisition will be a great asset to Serentis".

Peter Keen commented "The fast proof of principle business model operated by Serentis optimises the chances of success for all the stakeholders in the business. That said it also helps if you have knowledgeable investors and experienced management, so I am delighted to have the opportunity of joining the investor and management team at Serentis, most of whom I know well, and playing my role in building a successful company. "

Serentis Ltd 23 Cambridge Science Park Milton Road Cambridge CB4 0EY UK  
telephone +44 (0) 1223 432500 fax: +44 (0) 1223 432501 email [info@serentis-pharma.com](mailto:info@serentis-pharma.com) [www.serentis-pharma.com](http://www.serentis-pharma.com)

Enquiries:

Serentis Inc

Tim Sharpington, Chief Executive Officer

Tel: + 44 (0)1223 437028; email: Tim Sharpington

Notes to Editors:

About Serentis Inc.

Serentis Inc is a privately owned biopharmaceutical company developing a clinical-stage pipeline of products in areas of unmet medical need. Its initial focus is in the areas of dermatology, wound care and topically applied products. Serentis has in-house, low risk discovery and development capabilities and intends to use its core skills by licensing near-clinical stage products and technologies. The development model undertaken by Serentis is based on a fast to proof-of-principle approach.

Serentis was incorporated in Delaware in 2006 and its current operations are based in Cambridge, UK through its wholly owned subsidiary Serentis Ltd. It completed a \$20 million (£10 million) Series A financing in June 2007 jointly led by MVM Life Science Partners LLP, Apposite Capital LLP and Novo A/S.